Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Najib Dally, Myriam Baranes, Luiza Akria, Marat Kashlikov, Khalil Tarabia, Adi Sharabi-Nov, Celia Suriu & Andrei Braester. (2023) Ethnic disparities in presentation but not outcome in multiple myeloma patients: a multicenter retrospective study in Northern Israel. Leukemia & Lymphoma 0:0, pages 1-8.
Read now
Read now
Dorival Mendes Rodrigues-Junior, Maria Fernanda de Andrade Pelarin, Helena Bonciani Nader, André Luiz Vettore & Maria Aparecida Silva Pinhal. (2021) MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase. OncoTargets and Therapy 14, pages 455-467.
Read now
Read now
Croix C. Fossum, Stephanie Navarro, Albert J. Farias & Leslie K. Ballas. (2021) Racial disparities in the use of palliative radiotherapy for black patients with multiple myeloma in the United States. Leukemia & Lymphoma 62:13, pages 3235-3243.
Read now
Read now
Michael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, Tim Synold, Xiwei Wu, Shu Tao, Samantha N. Hammond, Ralf Buettner, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, Flavia Pichiorri, Firoozeh Sahebi, James F. Sanchez, Arnab Chowdhury, Amrita Krishnan, Stephen J. Forman & Steven T. Rosen. (2020) Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. Leukemia & Lymphoma 61:7, pages 1669-1677.
Read now
Read now
Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, Evangelos Terpos & Meletios A Dimopoulos. (2019) Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. Expert Review of Anticancer Therapy 19:11, pages 921-928.
Read now
Read now
Thomas A. Guerrero-Garcia, Sara Gandolfi, Jacob P. Laubach, Teru Hideshima, Dharminder Chauhan, Constantine Mitsiades, Kenneth C. Anderson & Paul G. Richardson. (2018) The power of proteasome inhibition in multiple myeloma. Expert Review of Proteomics 15:12, pages 1033-1052.
Read now
Read now
Nishitha Thumallapally, Hana Yu, Divya Asti, Adarsh Vennepureddy & Terenig Terjanian. (2016) Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?. OncoTargets and Therapy 9, pages 4843-4858.
Read now
Read now
Wendong Chen, Yicheng Yang, Yi Chen, Fen Du & Huan Zhan. (2016) Cost-effectiveness of bortezomib for multiple myeloma: a systematic review. ClinicoEconomics and Outcomes Research 8, pages 137-151.
Read now
Read now
Luciano J. Costa, Parameswaran N. Hari & Shaji K. Kumar. (2016) Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leukemia & Lymphoma 57:12, pages 2827-2832.
Read now
Read now
Andrzej J. Jakubowiak, Marco Campioni, Ágnes Benedict, Ivan Houisse, Eszter Tichy, Andromachi Giannopoulou, Sanjay K. Aggarwal, Beth L. Barber & Sumeet Panjabi. (2016) Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. Journal of Medical Economics 19:11, pages 1061-1074.
Read now
Read now
S. Z. Usmani, J. D. Cavenagh, A. R. Belch, C. Hulin, S. Basu, D. White, A. Nooka, A. Ervin-Haynes, W. Yiu, Y. Nagarwala, A. Berger, C. G. Pelligra, S. Guo, G. Binder, C. J. Gibson & T. Facon. (2016) Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. Journal of Medical Economics 19:3, pages 243-258.
Read now
Read now
Articles from other publishers (61)
Ying Chen, Meiling Tang, Yuxin Fu, Xinran Zhuang, Rongfang Wei & Yan Chen. (2023) A prognostic nomogram and risk classification system of elderly patients with extraosseous plasmacytoma: a SEER database analysis. Journal of Cancer Research and Clinical Oncology.
Crossref
Crossref
Maria-Victoria Mateos, Sikander Ailawadhi, Luciano J. Costa, Shakira J. Grant, Lalit Kumar, Mohamad Mohty, Didem Aydin & Saad Z. Usmani. (2023) Global disparities in patients with multiple myeloma: a rapid evidence assessment. Blood Cancer Journal 13:1.
Crossref
Crossref
Kimberley Doucette, Allison O. Taylor, Bryan Chan, Xiaoyang Ma, Jaeil Ahn, David H. Vesole & Catherine Lai. (2023) Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis. Annals of Hematology 102:6, pages 1443-1458.
Crossref
Crossref
Andrea Anampa-Guzmán, Sara Taveras Alam, Inas Abuali & Samer Al Hadidi. (2022) Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review. Clinical Hematology International 5:1, pages 29-37.
Crossref
Crossref
Lauren C. Peres, Christelle M. Colin-Leitzinger, Mingxiang Teng, Julie Dutil, Raghunandan R. Alugubelli, Gabriel DeAvila, Jamie K. Teer, Dongliang Du, Qianxing Mo, Erin M. Siegel, Oliver A. Hampton, Melissa Alsina, Jason Brayer, Brandon Blue, Rachid Baz, Ariosto S. Silva, Taiga Nishihori, Kenneth H. Shain & Nancy Gillis. (2022) Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Advances 6:12, pages 3767-3778.
Crossref
Crossref
Patrick Hagen, Jiwang Zhang & Kevin Barton. (2022) High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer Journal 12:5.
Crossref
Crossref
Bindu KanapuruLaura L. FernandesLola A. Fashoyin-Aje, Andrea C. Baines, Vishal BhatnagarRachel ErshlerThomas GwisePaul KluetzRichard PazdurElizabeth Pulte, Yuan-Li Shen & Nicole Gormley. (2022) Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. Blood Advances 6:6, pages 1684-1691.
Crossref
Crossref
Catherine R. Marinac, Dong Hoon Lee, Graham A. Colditz, Timothy R. Rebbeck, Bernard Rosner, Mark Bustoros, Irene M. Ghobrial & Brenda M. Birmann. (2022) Regular Aspirin Use and Mortality in Patients with Multiple Myeloma. Cancer Epidemiology, Biomarkers & Prevention 31:2, pages 479-485.
Crossref
Crossref
Lauren C. Peres, Doris K. Hansen, Francesco Maura & Dickran Kazandjian. (2022) The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.. Seminars in Oncology 49:1, pages 3-10.
Crossref
Crossref
Mary Jane Sneyd, Andrew R. Gray & Ian M. Morison. (2021) Trends in survival from myeloma, 1990–2015: a competing risks analysis. BMC Cancer 21:1.
Crossref
Crossref
Romil Patel, Junsheng Ma, Qaiser Bashir, Ruby Delgado, Gabriela Rondon, Uday R. Popat, Chitra M. Hosing, Yago Nieto, Partow Kebriaei, Amin M. Alousi, May Daher, Rohtesh Mehta, Samer Srour, Donna M. Weber, Sheeba K. Thomas, Hans C. Lee, Krina K. Patel, Robert Z. Orlowski, Elizabeth S. Shpall, Richard E. Champlin, Neeraj Saini & Muzaffar H. Qazilbash. (2021) Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity‐score matched analysis. American Journal of Hematology 96:12.
Crossref
Crossref
Patrizia Virdis, Rossana Migheli, Valentina Bordoni, Francesco Fiorentino, Luca Sanna, Irene Marchesi, Giorgio Pintore, Grazia Galleri, Maria Muroni, Luigi Bagella, Claudio Fozza, Maria De Miglio & Luigi Podda. (2021) Clarifying the molecular mechanism of tomentosin‑induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis. International Journal of Molecular Medicine 48:6.
Crossref
Crossref
Maira A. Castañeda-Avila, Bill M. Jesdale, Ariel Beccia, Ganga S. Bey & Mara M. Epstein. (2021) Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity. Cancer Causes & Control 32:9, pages 1021-1028.
Crossref
Crossref
Laurent Garderet, Giulia Sbianchi, Simona Iacobelli, Didier Blaise, Jenny L. Byrne, Peter Remenyi, Jane F. Apperley, Cyrille Touzeau, Cecilia Isaksson, Paul Browne, Jiri Mayer, Stig Lenhoff, Soledad Gonzalez Muniz, Rocio Parody Porras, Grzegorz Basak, Xavier Poire, Marek Trneny, Arnon Nagler, Mariagrazia Michieli, Alina Tanase, Linda Koster, Patrick J. Hayden, Meral Beksac, Stefan Schönland & Ibrahim Yakoub‐Agha. (2021) Prognostic impact of early‐versus‐late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT. European Journal of Haematology 106:5, pages 708-715.
Crossref
Crossref
Gurbakhash Kaur, Mateo Mejia Saldarriaga, Nishi Shah, Donna D. Catamero, Lihua Yue, Nadia Ashai, Niyati Goradia, Joshua Heisler, Zhengrui Xiao, Natasha Ghalib, Tonya Aaron, Daniel Cole, Rebecca Foreman, Ioannis Mantzaris, Olga Derman, Lizamarie Bachier, R. Alejandro Sica, Noah Kornblum, Ira Braunschweig, Aditi Shastri, Sanjay Goel, Amit Verma & Murali Janakiram. (2021) Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data. Clinical Lymphoma Myeloma and Leukemia 21:4, pages e384-e397.
Crossref
Crossref
Congyang Huang, Hanshan Liu, Li Jia, Min Lu & Suyun Hu. (2021) Survival Disparities in Multiple Myeloma by Health Insurance Status among US Non-Elderly Adults: A SEER-Based Comparative Analysis. Acta Haematologica 144:5, pages 542-550.
Crossref
Crossref
Dong Hoon Lee, Teresa T. Fung, Fred K. Tabung, Catherine R. Marinac, Elizabeth E. Devore, Bernard A. Rosner, Irene M. Ghobrial, Graham A. Colditz, Edward L. Giovannucci & Brenda M. Birmann. (2020) Prediagnosis dietary pattern and survival in patients with multiple myeloma. International Journal of Cancer 147:7, pages 1823-1830.
Crossref
Crossref
Debra J. Bergstrom, Rami Kotb, Martha L. Louzada, Heather J. Sutherland, Sofia Tavoularis, Christopher P. Venner, Julie Côté, Richard LeBlanc, Anthony Reiman, Michael Sebag, Kevin W. Song, Gabriele Colasurdo, Aldo Del Col, David McMullen, Annette E. Hay, Nicole M.B. Laferriere, Arleigh B. Robertson McCurdy, Jean Roy, Julie L. Stakiw, Suzanne M. Trudel, Darrell J. White, Fraser W. Loveys, Edward Randell & Kamilia S. Rizkalla. (2020) Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. Clinical Lymphoma Myeloma and Leukemia 20:7, pages e352-e367.
Crossref
Crossref
Smith Giri, Scott F. Huntington, Rong Wang, Amer M. Zeidan, Nikolai Podoltsev, Steven D. Gore, Xiaomei Ma, Cary P. Gross, Amy J. Davidoff & Natalia Neparidze. (2020) Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 4:10, pages 2245-2253.
Crossref
Crossref
Catherine R. Marinac, Irene M. Ghobrial, Brenda M. Birmann, Jenny Soiffer & Timothy R. Rebbeck. (2020) Dissecting racial disparities in multiple myeloma. Blood Cancer Journal 10:2.
Crossref
Crossref
Reiko Isa, Nobuhiko Uoshima, Ryoichi Takahashi, Sonoko Nakano-Akamatsu, Eri Kawata, Hiroto Kaneko, Kazuho Shimura, Yuri Kamitsuji, Tomoko Takimoto-Shimomura, Shinsuke Mizutani, Yoshiaki Chinen, Muneo Ohshiro, Takahiro Fujino, Yuka Kawaji, Hitoji Uchiyama, Nana Sasaki, Taku Tsukamoto, Yuji Shimura, Tsutomu Kobayashi, Masafumi Taniwaki & Junya Kuroda. (2019) Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. Annals of Hematology 99:1, pages 137-145.
Crossref
Crossref
Ying Liu, Hai‐Mei Liang, Yu‐Qi Lv, Shao‐Mei Tang & Peng Cheng. (2019) Blockade of SDF‐1/CXCR4 reduces adhesion‐mediated chemoresistance of multiple myeloma cells via interacting with interleukin‐6. Journal of Cellular Physiology 234:11, pages 19702-19714.
Crossref
Crossref
Ronan W. Hsieh, Ronald S. Go, Jithma P. Abeykoon, Prashant Kapoor, Shaji K. Kumar, Morie A. Gertz, Francis K. Buadi, Nelson Leung, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Rahma M. Warsame, Angela Dispenzieri, Martha Q. Lacy, Robert A. Kyle, S. Vincent Rajkumar & Jonas Paludo. (2019) Characteristics of long‐term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer 125:20, pages 3574-3581.
Crossref
Crossref
Karen Sweiss, Annie Oh, Gregory S. Calip, Damiano Rondelli & Pritesh Patel. (2019) Superior Survival in African American Patients Who Underwent Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 19:8, pages e506-e511.
Crossref
Crossref
Nathanael R. Fillmore, Sarvari V. YellapragadaChizoba IfeorahAnsh Mehta, Diana Cirstea, Paul S. White, Gustavo RiveroAndrew ZimolzakSaiju PyarajanNhan Do, Mary Brophy & Nikhil C. Munshi. (2019) With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood 133:24, pages 2615-2618.
Crossref
Crossref
Dong Hoon Lee, Teresa T Fung, Fred K Tabung, Graham A Colditz, Irene M Ghobrial, Bernard A Rosner, Edward L Giovannucci & Brenda M Birmann. (2019) Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies. JNCI Cancer Spectrum 3:2.
Crossref
Crossref
Siddhartha Ganguly, Sham Mailankody & Sikander Ailawadhi. (2019) Many Shades of Disparities in Myeloma Care. American Society of Clinical Oncology Educational Book:39, pages 519-529.
Crossref
Crossref
Dorival Rodrigues‑Junior, Tha�s Biassi, Gabriela de Albuquerque, Viviane Carlin, Marcus Buri, Joel Machado‑Junior & Andre Vettore. (2019) Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment. Molecular Medicine Reports.
Crossref
Crossref
Elisa Bergaggio, Chiara Riganti, Giulia Garaffo, Nicoletta Vitale, Elisabetta Mereu, Cecilia BandiniElisa Pellegrino, Verdiana Pullano, Paola OmedèKatia TodoertiLuciano Cascione, Valentina Audrito, Anna Riccio, Antonio Rossi, Francesco Bertoni, Silvia Deaglio, Antonino Neri, Antonio Palumbo & Roberto Piva. (2019) IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood 133:2, pages 156-167.
Crossref
Crossref
Reinhold Munker & Gregory Monohan. (2019) Progress in multiple myeloma. Indian Journal of Medical Research 149:6, pages 693.
Crossref
Crossref
Roel Vermeulen, Fatemeh Saberi Hosnijeh, Barbara Bodinier, Lützen Portengen, Benoît Liquet, Javiera Garrido‐Manriquez, Henk Lokhorst, Ingvar A. Bergdahl, Soterios A. Kyrtopoulos, Ann‐Sofie Johansson, Panagiotis Georgiadis, Beatrice Melin, Domenico Palli, Vittorio Krogh, Salvatore Panico, Carlotta Sacerdote, Rosario Tumino, Paolo Vineis, Raphaële Castagné, Marc Chadeau‐Hyam, Maria Botsivali, Aristotelis Chatziioannou, Ioannis Valavanis, Jos C.S. Kleinjans, Theo M.C.M. de Kok, Hector C. Keun, Toby J. Athersuch, Rachel Kelly, Per Lenner, Goran Hallmans, Euripides G. Stephanou, Antonis Myridakis, Manolis Kogevinas, Lucia Fazzo, Marco De Santis, Pietro Comba, Benedetta Bendinelli, Hannu Kiviranta, Panu Rantakokko, Riikka Airaksinen, Paivi Ruokojarvi, Mark Gilthorpe, Sarah Fleming, Thomas Fleming, Yu‐Kang Tu, Thomas Lundh, Kuo‐Liong Chien, Wei J. Chen, Wen‐Chung Lee, Chuhsing Kate Hsiao, Po‐Hsiu Kuo, Hung Hung & Shu‐Fen Liao. (2018) Pre‐diagnostic blood immune markers, incidence and progression of B‐cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses. International Journal of Cancer 143:6, pages 1335-1347.
Crossref
Crossref
Cheryl Jacobs Smith, Stefan Ambs & Ola Landgren. (2018) Biological determinants of health disparities in multiple myeloma. Blood Cancer Journal 8:9.
Crossref
Crossref
Jennifer Huang, Sharon Phillips, Michael Byrne, Wichai Chinratanalab, Brian G. Engelhardt, Stacey A. Goodman, Shelton L. Harrell, Madan Jagasia, Adetola Kassim, Kyle T. Rawling, Bipin N. Savani, Salyka Sengsayadeth & R. Frank Cornell. (2018) Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplantation 53:6, pages 701-707.
Crossref
Crossref
Luz Tarín-Arzaga, Daniela Arredondo-Campos, Victor Martínez-Pacheco, Odra Martínez-González, Alba Ramírez-López, Andrés Gómez-De León, Cesar Homero Gutiérrez-Aguirre, Olga Cantú-Rodríguez, José Carlos Jaime-Pérez & David Gómez-Almaguer. (2018) Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico. Cancer 124:9, pages 1946-1953.
Crossref
Crossref
Catherine R. Marinac, Brenda M. Birmann, I-Min Lee, Bernard A. Rosner, Mary K. Townsend, Edward Giovannucci, Timothy R. Rebbeck, Julie E. Buring & Graham A. Colditz. (2018) Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. British Journal of Cancer 118:7, pages 1013-1019.
Crossref
Crossref
E. Dianne Pulte, Lei Nie, Nicole Gormley, Kirsten B. Goldberg, Amy McKee, Ann Farrell & Richard Pazdur. (2018) Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Advances 2:2, pages 116-119.
Crossref
Crossref
Susan M. White. (2018) Malignant Lesions in the Dentomaxillofacial Complex. Radiologic Clinics of North America 56:1, pages 63-76.
Crossref
Crossref
Jacob P. Laubach, Philippe Moreau, Meletios A. Dimopoulos & Paul G. Richardson. 2018. Multiple Myeloma and Other Plasma Cell Neoplasms. Multiple Myeloma and Other Plasma Cell Neoplasms
73
96
.
Sara Gandolfi, Jacob P. Laubach, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson & Paul G. Richardson. (2017) The proteasome and proteasome inhibitors in multiple myeloma. Cancer and Metastasis Reviews 36:4, pages 561-584.
Crossref
Crossref
Christopher G. Pelligra, Kejal Parikh, Shien Guo, Conor Chandler, Jorge Mouro, Safiya Abouzaid & Sikander Ailawadhi. (2017) Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States. Clinical Therapeutics 39:10, pages 1986-2005.e5.
Crossref
Crossref
Jeffrey R. Schriber, Parameswaran N. Hari, Kwang Woo Ahn, Mingwei Fei, Luciano J. Costa, Mohamad A. Kharfan‐Dabaja, Miguel Angel‐Diaz, Robert P. Gale, Siddharatha Ganguly, Saulius K. Girnius, Shahrukh Hashmi, Attaphol Pawarode, David H. Vesole, Peter H. Wiernik, Baldeep M. Wirk, David I. Marks, Taiga Nishihori, Richard F. Olsson, Saad Z. Usmani, Tomer M. Mark, Yago L. Nieto & Anita D'Souza. (2017) Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer 123:16, pages 3141-3149.
Crossref
Crossref
Hollie Devine & Daniel Verina. (2017) Young Adults with Multiple Myeloma. Seminars in Oncology Nursing 33:3, pages 316-331.
Crossref
Crossref
Sikander Ailawadhi, Kirtipal Bhatia, Sonikpreet Aulakh, Zahara Meghji & Asher Chanan-Khan. (2017) Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?. Current Hematologic Malignancy Reports 12:4, pages 309-316.
Crossref
Crossref
Megan M. Sharkey, Daniel McKavanagh, Euan Walpole, Peter Mollee & Samantha A. Hollingworth. (2017) Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting. International Journal of Clinical Pharmacy 39:4, pages 836-843.
Crossref
Crossref
M B Abid, D Christopher, M A Abid, M L Poon, L K Tan, L P Koh & W J Chng. (2017) Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore. Bone Marrow Transplantation 52:7, pages 1044-1046.
Crossref
Crossref
Robert F. Cornell, Anita D'Souza, Adetola A. Kassim, Luciano J. Costa, Racquel D. Innis-Shelton, Mei-Jie Zhang, Jiaxing Huang, Muneer Abidi, Jack Aiello, Gorgun Akpek, Asad Bashey, Qaiser Bashir, Jan Cerny, Raymond Comenzo, Miguel Angel Diaz, César Freytes, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Shahrukh Hashmi, Leona Holmberg, Nasheed Hossain, Rammurti T. Kamble, Mohamed Kharfan-Dabaja, Tamila Kindwall-Keller, Robert Kyle, Shaji Kumar, Hillard Lazarus, Cindy Lee, Angelo Maiolino, David I. Marks, Kenneth Meehan, Joe Mikhael, Rajneesh Nath, Taiga Nishihori, Richard F. Olsson, Muthalagu Ramanathan, Ayman Saad, Sachiko Seo, Saad Usmani, David Vesole, Ravi Vij, Dan Vogl, Baldeep M. Wirk, Jean Yared, Amrita Krishnan, Tomer Mark, Yago Nieto & Parameswaran Hari. (2017) Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation 23:2, pages 269-277.
Crossref
Crossref
Luciano J. Costa, Ilene K. BrillJames OmelKelly GodbyShaji K. Kumar & Elizabeth E. Brown. (2017) Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Advances 1:4, pages 282-287.
Crossref
Crossref
Noa Biran, Scott D. Rowley, David H. Vesole, Shijia Zhang, Michele L. Donato, Joshua Richter, Alan P. Skarbnik, Andrew Pecora & David S. Siegel. (2016) A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation 22:12, pages 2165-2171.
Crossref
Crossref
Luciano J. Costa, Ilene K. Brill & Elizabeth E. Brown. (2016) Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. Cancer 122:20, pages 3183-3190.
Crossref
Crossref
Michela Colombo, Serena Galletti, Gaetano Bulfamante, Monica Falleni, Delfina Tosi, Katia Todoerti, Elisa Lazzari, Leslie A. Crews, Catriona H.M. Jamieson, Sara Ravaioli, Francesco Baccianti, Silvia Garavelli, Natalia Platonova, Antonino Neri & Raffaella Chiaramonte. (2016) Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget 7:35, pages 56013-56029.
Crossref
Crossref
Maximilian Merz, Lina Jansen, Felipe A. Castro, Jens Hillengass, Hans Salwender, Katja Weisel, Christof Scheid, Sabine Luttmann, Katharina Emrich, Bernd Holleczek, Alexander Katalinic, Alice Nennecke, Christian Straka, Christian Langer, Monika Engelhardt, Hermann Einsele, Nicolaus Kröger, Dietrich Beelen, Peter Dreger, Hermann Brenner & Hartmut Goldschmidt. (2016) Survival of elderly patients with multiple myeloma—Effect of upfront autologous stem cell transplantation. European Journal of Cancer 62, pages 1-8.
Crossref
Crossref
Gordon Cook, A John Ashcroft, David A Cairns, Cathy D Williams, Julia M Brown, Jamie D Cavenagh, John A Snowden, Christopher Parrish, Kwee Yong, Jim Cavet, Hannah Hunter, Jenny M Bird, Guy Pratt, Sally Chown, Ernest Heartin, Sheila O'Connor, Mark T Drayson, Anna Hockaday & Treen C M Morris. (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. The Lancet Haematology 3:7, pages e340-e351.
Crossref
Crossref
R F Cornell & A A Kassim. (2016) Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplantation 51:4, pages 479-491.
Crossref
Crossref
Weijuan LiR. Frank CornellDaniel LenihanDavid SloskyMadan JagasiaGregory PiazzaJavid Moslehi. (2016) Cardiovascular Complications of Novel Multiple Myeloma Treatments. Circulation 133:9, pages 908-912.
Crossref
Crossref
Dianne Pulte, Lina Jansen, Felipe A. Castro, Katharina Emrich, Alexander Katalinic, Bernd Holleczek & Hermann Brenner. (2015) Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. British Journal of Haematology 171:2, pages 189-196.
Crossref
Crossref
Jonas A de Souza & Lori Muffly. (2015) The overlooked COST of multiple myeloma. The Lancet Haematology 2:10, pages e394-e395.
Crossref
Crossref
David G. Crockett & Fausto R. LoberizaJrJr. (2015) Persistent Disparities in Adult Hematopoietic Cell Transplantation. Current Hematologic Malignancy Reports 10:3, pages 192-198.
Crossref
Crossref
Muhammad A. Mir, Prashant Kapoor, Shaji Kumar, Shivlal Pandey, Angela Dispenzieri, Martha Q. Lacy, David Dingli, William Hogan, Francis Buadi, Suzanne Hayman, Manish Gandhi & Morie A. Gertz. (2015) Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. Clinical Lymphoma Myeloma and Leukemia 15:6, pages 349-357.e2.
Crossref
Crossref
Vishal Bhatnagar, Yin Wu, Olga G. Goloubeva, Kathleen T. Ruehle, Todd E. Milliron, Carolynn G. Harris, Aaron P. Rapoport, Saul Yanovich, Edward A. Sausville, Maria R. Baer & Ashraf Z. Badros. (2015) Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study. Cancer 121:7, pages 1064-1070.
Crossref
Crossref
Dan Wu, Xinyi Guo, Jing Su, Ruoying Chen, Dmitriy Berenzon, Martin Guthold, Keith Bonin, Weiling Zhao & Xiaobo Zhou. (2015) CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1853:2, pages 338-347.
Crossref
Crossref
Claudia V. Andreu-Vieyra & James R. Berenson. (2014) The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Therapeutic Advances in Hematology 5:6, pages 197-210.
Crossref
Crossref